Avidity biosciences announces pricing of upsized public offering of common stock

San diego , sept. 11, 2025 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced the pricing of its upsized underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $40.00 per share.
RNA Ratings Summary
RNA Quant Ranking